SCHEMBL15917694

SCHEMBL15917694

CS(=O)(=O)Nc1cccc(-c2nccc(NCc3ccc(F)cc3C(F)(F)F)n2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 18/20 0.66
CYP3A4 P08684 18/20 0.66
CYP2C19 P33261 13/20 0.66
CYP2D6 P10635 12/20 0.66
CLK4 Q9HAZ1 7/20 0.66
USP2 O75604 6/20 0.66
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
CYP2C9 P11712 7/20 0.64
GLA P06280 3/20 0.63
LMNA P02545 4/20 0.62
MAPK1 P28482 5/20 0.61
ALDH1A1 P00352 4/20 0.61
HSD17B10 Q99714 4/20 0.61
MAPT P10636 2/20 0.61
HPGD P15428 2/20 0.61
HIF1A Q16665 2/20 0.61
ALOX15 P16050 6/20 0.60
TSHR P16473 3/20 0.59
TP53 P04637 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15917854 0.89 CYP1A2 (0.70) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL1172063 0.74 CYP1A2 (0.66) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL14555013 0.74 CYP1A2 (0.53) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL14554837 0.74 HDAC3 (0.46) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL14554932 0.74 CYP1A2 (0.52) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL15917388 0.74 VNN1 (0.53) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL14554902 0.73 CLK4 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL14486092 0.73 CYP1A2 (0.52) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL14554931 0.71 CLK4 (0.47) CYP1A2CYP3A4CYP2C19CYP2D6CLK4
SCHEMBL14486182 0.70 CYP1A2 (0.46) CYP1A2CYP3A4CYP2C19CYP2D6CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2729459-B1 SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER MERCK PATENT GMBH (DE) 2018-08-22 EP disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer CCNH, CCNA1, MYC CYP1A2 584/4885CYP3A4 2492/4885CYP2C19 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.